Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy

Best Practice and Research: Clinical Haematology

Volumn 25, Issue 4, 2012, Pages 427-435

  Garcia Manero, Guillermo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

acute myelogenous leukemia; AML; HDAC; histone deacetylase inhibitors; treatment; vorinostat

Indexed keywords

ARSENIC TRIOXIDE; CYTARABINE; ENTINOSTAT; GYRASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IDARUBICIN; MIDOSTAURIN; MOCETINOSTAT; PANOBINOSTAT; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; RETINOIC ACID; SORAFENIB; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); CONCENTRATION RESPONSE; DIARRHEA; DRUG HALF LIFE; DRUG SAFETY; DRUG SCREENING; EVENT FREE SURVIVAL; HISTONE ACETYLATION; HUMAN; IN VITRO STUDY; LEUKEMIA CELL; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; TREATMENT DURATION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; CLINICAL TRIALS, PHASE I AS TOPIC; CYTARABINE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; IDARUBICIN; LEUKEMIA, MYELOID, ACUTE;

EID: 84870698177     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2012.10.005     Document Type: Review

References (37)

1. A.H. Shih, O. Abdel-Wahab, and J.P. Patel The role of mutations in epigenetic regulators in myeloid malignancies Nat Rev Cancer 12 9 2012 599 612
2. C. Thiede, C. Steudel, and B. Mohr Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis Blood 99 12 2002 4326 4335
3. J. Yates, O. Glidewell, and P. Wiernik Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study Blood 60 2 1982 454 462
4. P.A. Cassileth, D.P. Harrington, and F.R. Appelbaum Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission N Engl J Med 339 23 1998 1649 1656
5. H.F. Fernandez, Z. Sun, and X. Yao Anthracycline dose intensification in acute myeloid leukemia N Engl J Med 361 13 2009 1249 1259
6. B. Lowenberg, G.J. Ossenkoppele, and W. van Putten High-dose daunorubicin in older patients with acute myeloid leukemia N Engl J Med 361 13 2009 1235 1248
7. T. Fischer, R.M. Stone, and D.J. Deangelo Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3 J Clin Oncol 28 28 2010 4339 4345
8. W. Zhang, M. Konopleva, and Y.X. Shi Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia J Natl Cancer Inst 100 3 2008 184 198
9. P.P. Zarrinkar, R.N. Gunawardane, and M.D. Cramer AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) Blood 114 14 2009 2984 2992
10. F. Ravandi, J.E. Cortes, and D. Jones Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia J Clin Oncol 28 11 2010 1856 1862
11. E. Jabbour, H. Kantarjian, and F. Ravandi A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome Cancer 117 6 2011 1236 1244
12. F. Ravandi, E. Estey, and D. Jones Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin J Clin Oncol 27 4 2009 504 510
13. C.D. Bloomfield, A.S. Ruppert, and K. Mrozek Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) study 8461 Ann Hematol 83 Suppl. 1 2004 S84 S85
14. S. Schnittger, C. Schoch, and W. Kern Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype Blood 106 12 2005 3733 3739
15. G. Garcia-Manero, and S.D. Gore Future directions for the use of hypomethylating agents Semin Hematol 42 3 Suppl. 2 2005 S50 S59
16. P.A. Marks, T. Miller, and V.M. Richon Histone deacetylases Curr Opin Pharmacol 3 4 2003 344 351
17. V.M. Richon, Y. Webb, and R. Merger Second generation hybrid polar compounds are potent inducers of transformed cell differentiation Proc Natl Acad Sci U S A 93 12 1996 5705 5708
18. G. Garcia-Manero, and J.P. Issa Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents Cancer Invest 23 7 2005 635 642
19. M. Duvic, R. Talpur, and X. Ni Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Blood 109 1 2007 31 39
20. R.L. Piekarz, R. Robey, and V. Sandor Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report Blood 98 9 2001 2865 2868
21. G. Garcia-Manero, H. Yang, and C. Bueso-Ramos Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes Blood 111 3 2008 1060 1066
22. G. Garcia-Manero, S. Assouline, and J. Cortes Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia Blood 112 4 2008 981 989
23. F. Giles, T. Fischer, and J. Cortes A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies Clin Cancer Res 12 15 2006 4628 4635
24. I. Gojo, A. Jiemjit, and J.B. Trepel Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias Blood 109 7 2007 2781 2790
25. W.K. Kelly, V.M. Richon, and O. O'Connor Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously Clin Cancer Res 9 10 Pt 1 2003 3578 3588
26. A.O. Soriano, H. Yang, and S. Faderl Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome Blood 110 7 2007 2302 2308
27. H. Yang, K. Hoshino, and B. Sanchez-Gonzalez Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid Leuk Res 29 7 2005 739 748
28. S.D. Gore, S. Baylin, and E. Sugar Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms Cancer Res 66 12 2006 6361 6369
29. B. Sanchez-Gonzalez, H. Yang, and C. Bueso-Ramos Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor Blood 108 4 2006 1174 1182
30. P.J. Cook, B.G. Ju, and F. Telese Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions Nature 458 7238 2009 591 596
31. D.C. Marchion, E. Bicaku, and A.I. Daud Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid J Cell Biochem 92 2 2004 223 237
32. K. Shiozawa, T. Nakanishi, and M. Tan Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias Clin Cancer Res 15 5 2009 1698 1707
33. T.M. Kadia, H. Yang, and A. Ferrajoli A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia Br J Haematol 150 1 2010 72 82
34. G. Garcia-Manero, S. Faderl, and F. Giles A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes Haematologica 87 8 2002 804 807
35. G. Garcia-Manero, F.P. Tambaro, and N.B. Bekele Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome J Clin Oncol 30 2012 2204 2210
36. P. Greenberg, C. Cox, and M.M. LeBeau International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 6 1997 2079 2088
37. Y. Hu, W. Lu, and G. Chen Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound beta-phenylethyl isothiocyanate Blood 116 15 2010 2732 2741